Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS)

Summary

This will be an open label treatment extension phase in patients with ALS who have previously participated in the double blind, placebo-controlled ALS-TAL-201 study. This study will make talampanel treatment available to all subjects who completed the double blind placebo-controlled phase of ALS-TAL-201 study and where the investigator and patient consider it to be in the patient's interest to receive talampanel 50mg three times daily (tid). It will also enable the exploration of long-term safety and tolerability of talampanel 50mg tid.

Timeline

Start

2009-09

Primary completion

2010-06

Completion

2010-06

Drugs

Indications